Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Roswell Park Cancer Institute
Roswell Park Cancer Institute
First Affiliated Hospital of Zhejiang University
Roswell Park Cancer Institute
Obstetrics & Gynecology Hospital of Fudan University
Chinese PLA General Hospital
Columbia University
Peking University Third Hospital
Hospital Israelita Albert Einstein
Fudan University
Women's Hospital School Of Medicine Zhejiang University
Chinese PLA General Hospital
Ruijin Hospital
Maastricht Radiation Oncology
Huazhong University of Science and Technology
Indiana University